Cargando…

Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis

BACKGROUND: Primary membranous nephropathy (MN), sometimes referred to as idiopathic membranous nephropathy (IMN), is a kind of MN whose pathogenesis is yet unclear. According to research reports, the incidence of IMN is about 9.8–26.8%, and it is on the rise. METHODS: The computer retrieves eight d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Huijuan, Shen, Jun, Sun, Jieqiong, Sun, Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581616/ https://www.ncbi.nlm.nih.gov/pubmed/36276580 http://dx.doi.org/10.1155/2022/5393797

Ejemplares similares

Retracted: Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: and Biomechanics, Applied Bionics
Publicado: (2023)

Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis
por: Lu, WanJun, et al.
Publicado: (2020)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis
por: Zhong, Hongzhen, et al.
Publicado: (2020)

Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy
por: Cheong, Jamie, et al.
Publicado: (2018)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience
por: Chen, Ping, et al.
Publicado: (2023)

Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review
por: Jeon, Soo-Jee, et al.
Publicado: (2022)

Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study
por: Zhang, Shasha, et al.
Publicado: (2023)

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

Efficacy and safety of different dosing regimens of rituximab in primary membranous nephropathy: protocol for a systematic review and meta-analysis
por: Xu, Yongxing, et al.
Publicado: (2023)

Efficacy and safety of Tripterygium wilfordii multiglucoside for idiopathic membranous nephropathy: a systematic review with bayesian meta-analysis
por: Wang, Hongyun, et al.
Publicado: (2023)

Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population
por: Lin, Shujun, et al.
Publicado: (2019)

Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis
por: Lin, Wenshan, et al.
Publicado: (2019)

Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis
por: Zhen, Chao, et al.
Publicado: (2022)

Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide–corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy
por: Wang, Qi, et al.
Publicado: (2021)

Efficacy and safety of 12 immunosuppressive agents for idiopathic membranous nephropathy in adults: A pairwise and network meta-analysis
por: Liu, Jiarong, et al.
Publicado: (2022)

Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
por: Bagchi, Soumita, et al.
Publicado: (2018)

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022)

Rituximab in patients with membranous nephropathy and kidney insufficiency
por: Guo, Yanhong, et al.
Publicado: (2022)

Immunosuppressive treatment for idiopathic membranous nephropathy: An updated network meta-analysis
por: Bao, Neng, et al.
Publicado: (2023)

Efficacy and Safety of Rituximab in Hepatitis B Virus–Associated PLA2R-Positive Membranous Nephropathy
por: Berchtold, Lena, et al.
Publicado: (2017)

Recurrent idiopathic membranous nephropathy in the renal allograft: successful treatment with the anti-CD20 monoclonal antibody rituximab
por: Ladino, Marco, et al.
Publicado: (2009)

Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal
por: Rojas-Rivera, Jorge Enrique, et al.
Publicado: (2019)

Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
por: Wang, Yao-Wei, et al.
Publicado: (2023)

Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience
por: Katsuno, Takayuki, et al.
Publicado: (2017)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy
por: Cheungpasitporn, Wisit, et al.
Publicado: (2016)

The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
por: Alberici, Federico, et al.
Publicado: (2023)

The Safety and Efficacy of Rituximab-Based Regimen in Atypical Membranous Nephropathy: A Single Center Retrospective Cohort Study
por: Liu, Yanan, et al.
Publicado: (2023)

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Rituximab in Primary Membranous Nephropathy With Severe CKD
por: Naik, Sachin, et al.
Publicado: (2023)

Immunosuppressive Treatment for Nephrotic Idiopathic Membranous Nephropathy: A Meta-Analysis Based on Chinese Adults
por: Xie, Guoqiang, et al.
Publicado: (2012)

Clinicopathological features of idiopathic membranous nephropathy combined with IgA nephropathy: a retrospective analysis of 9 cases
por: Hu, Ruimin, et al.
Publicado: (2016)

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
por: Cortazar, Frank B., et al.
Publicado: (2017)

Treatment of membranous nephropathy with crescent nephritis by rituximab: A case report
por: Zhang, Fan, et al.
Publicado: (2022)

Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy
por: Zhang, Chengning, et al.
Publicado: (2020)

Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis
por: Wu, Shanshan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ivard2rrnhrsopvkt3tnjjv1bn